Patents by Inventor Kevin Allen

Kevin Allen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190376028
    Abstract: Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.
    Type: Application
    Filed: August 13, 2019
    Publication date: December 12, 2019
    Applicant: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel E. Baetge
  • Patent number: 10465162
    Abstract: Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 5, 2019
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
  • Publication number: 20190328934
    Abstract: Disclosed are devices and methods for transplanting cells, such as pancreatic endoderm cells, into a host. The devices include a non-woven fabric external to a cell-excluding membrane, and the non-woven fabric and/or cell-excluding membrane can be perforated. Treatment of the host with immunosuppressive reagents, required to inhibit allograft rejection due to perforations in the cell delivery device, does not compromise maturation or function of transplanted pancreatic endoderm cells.
    Type: Application
    Filed: November 10, 2016
    Publication date: October 31, 2019
    Applicant: Viacyte, Inc.
    Inventors: Kevin Allen D'Amour, Evert Kroon, Michael Scott, Laura Martinson, Craig McGreevy
  • Publication number: 20190322247
    Abstract: The present invention is an apparatus for tire inflation designed to allow users to properly inflate, maintain, and monitor the condition of vehicle tires. The tire inflation device of present invention is comprising of: a carrying case having a housing, a lid attached to the housing using a hinge, a plurality of locking latches to lock the lid over the housing and a handle configured over the lid to allow easy transport of the tire inflating device. The tire inflation device further comprises, a control head assembly to control the working of the device, an air compressor coupled with the control head assembly to provide compressed air for inflation of tires, a hose assembly to connect the device with the vehicle tires and a plurality of power adapters to connect the device with the power source.
    Type: Application
    Filed: April 24, 2019
    Publication date: October 24, 2019
    Inventor: Kevin Allen Hibbard
  • Publication number: 20190307810
    Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 10, 2019
    Applicant: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Kevin Allen D'Amour
  • Publication number: 20190306275
    Abstract: A method for software development, installation, and management in a computer system may include: allowing first users to create components of applications; allowing second users, at a display of a web-browser-capable communications device, to build, edit, save, and compile new applications, using the components of the applications as end-user development tools, and to add the new applications to the library of applications; and allowing the second users, at the display of the web-browser-capable communications device, to download one or more of the new applications from the library of applications to mobile communications devices. When executed by the processor, the stored instructions control the computer system to perform functions that may include: connecting the mobile communications devices in a network using the downloaded one or more of the new applications; and causing information transfer to occur within the network that is independent of the processor of the computer system.
    Type: Application
    Filed: June 21, 2019
    Publication date: October 3, 2019
    Inventors: Kevin Allen BAUGH, Douglas Mark DILLON, Michele Kim CASEY, Barry Samuel HESS, David William PACHURA, Martea Denisa SCOTT
  • Patent number: 10421942
    Abstract: Disclosed herein are cell cultures comprising definitive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified definitive endoderm cells as well as methods for enriching, isolating and purifying definitive endoderm cells from other cell types.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: September 24, 2019
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Emmanuel E. Baetge
  • Patent number: 10391156
    Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: August 27, 2019
    Assignee: ViaCyte, Inc.
    Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
  • Patent number: 10394698
    Abstract: In one example in accordance with the present disclosure, a method may include receiving code corresponding to an HTML page structure including a plurality of executable JavaScript code and enumerating a branching path in the JavaScript code. The method may include determining a branch of the branching path that would not execute during normal operation of a browser executing the JavaScript code. The method may also include generating an artificial condition for the branch and executing the branch using the artificial condition.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: August 27, 2019
    Assignee: ENTIT SOFTWARE LLC
    Inventors: Kevin Allen Williams, Steve Alan Millar, Stephen Daniel Hardeman
  • Publication number: 20190255159
    Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
    Type: Application
    Filed: May 3, 2019
    Publication date: August 22, 2019
    Applicant: ViaCyte, Inc.
    Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
  • Patent number: 10376545
    Abstract: A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: August 13, 2019
    Assignee: ViaCyte, Inc.
    Inventors: Alan D. Agulnick, Kevin Allen D'Amour
  • Patent number: 10346210
    Abstract: Embodiments are directed towards push signaling to run jobs on available servers. Users may provide jobs or job instructions to a job control node. Job control node may determine one or more available job target nodes from among a plurality of managed nodes associated with the job control node. The job target nodes may be determined based on information included in the provided job instructions. If there are available job target nodes, the job control node may provide the job instructions to each available job target node. Further, the job control node may receive communications from one or more available job target nodes that indicates that the job target node is prepared and ready to execute the received job instructions. Next, the job control node may issue a job start command that triggers the prepared job target nodes to begin executing the provided job instructions.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: July 9, 2019
    Assignee: Chef Software, Inc.
    Inventors: Mark Andrew Anderson, Christopher James Brown, Kevin Allen Smith, John Braden Keiser
  • Publication number: 20190153439
    Abstract: This disclosure provides, among other things, a method for making a cDNA library. In some embodiments the method may comprise reverse transcribing mRNA to produce DNA:mRNA hybrids, treating the DNA:mRNA hybrids with RNAseH to produce mRNA fragments, and reverse transcribing the mRNA fragments.
    Type: Application
    Filed: November 20, 2017
    Publication date: May 23, 2019
    Inventors: Kevin Allen, Adam Morris
  • Patent number: 10294627
    Abstract: A system including a backfill protector including a skirt having an opening configured to receive a cover therein and a lip extending around a perimeter of the opening. The lip is configured to support the cover thereon, and the skirt further includes an inwardly-extending channel positioned adjacent to the lip.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: May 21, 2019
    Assignee: OPW FUELING COMPONENTS, LLC
    Inventors: Russell A. Bechler, Kevin Allen Webster
  • Publication number: 20190144822
    Abstract: Disclosed herein are cell cultures comprising dorsal and/or ventral PDX1-positive foregut endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified dorsal and/or ventral PDX1-positive foregut endoderm cells as well as methods for enriching, isolating and purifying dorsal and/or ventral PDX1-positive foregut endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of dorsal and/or ventral PDX1-positive foregut endoderm cells, are also disclosed.
    Type: Application
    Filed: November 26, 2018
    Publication date: May 16, 2019
    Applicant: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
  • Patent number: 10218163
    Abstract: A system including a sump having an inner volume and a junction box coupled to the sump. The junction box has a body defining an inner volume, and also has a first inlet and a second inlet, wherein each inlet is in fluid communication with the inner volume of the body. The junction box further has a first outlet and a second outlet, wherein each outlet is in fluid communication with the inner volume of the body such that a first wire is positionable in the first inlet and the first outlet and a second wire is positioned in the second inlet and the second outlet.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: February 26, 2019
    Assignee: OPW FUELING COMPONENTS, LLC
    Inventors: Daniel Christopher Long, Kevin Allen Webster, Charles J. Liebal, Jr., Daniel Lee Boyle, Wolfgang Emmanuel Sanyer, Glenn Michael Eckart, Kristopher A. Kane
  • Publication number: 20190055514
    Abstract: Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.
    Type: Application
    Filed: October 31, 2018
    Publication date: February 21, 2019
    Applicant: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Emmanuel E. Baetge
  • Publication number: 20190032008
    Abstract: This disclosure relates to compositions comprising human preprimitive streak cells and/or human mesendoderm cells as well as methods for their production. Additionally, disclosed herein are methods of identifying factors useful in the further differentiation of preprimitive streak and mesendoderm cell types.
    Type: Application
    Filed: October 2, 2018
    Publication date: January 31, 2019
    Applicant: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Evert Kroon, Emmanuel E. Baetge
  • Publication number: 20190015487
    Abstract: Disclosed herein are universal donor stem cells and cells derived therefrom and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming allogeneic immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor cells disclosed herein are pancreatic endoderm cells that do not express one or more MHC-Class I cell-surface proteins and whose expression of at least one NK activating ligand is disrupted or inhibited.
    Type: Application
    Filed: July 12, 2017
    Publication date: January 17, 2019
    Applicant: ViaCyte, Inc.
    Inventors: Anindita Bhoumik, Alan D. Agulnick, Kevin Allen D'Amour
  • Patent number: 10179902
    Abstract: This disclosure relates to compositions comprising human preprimitive streak cells and/or human mesendoderm cells as well as methods for their production. Additionally, disclosed herein are methods of identifying factors useful in the further differentiation of preprimitive streak and mesendoderm cell types.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: January 15, 2019
    Assignee: ViaCyte, Inc.
    Inventors: Kevin Allen D'Amour, Alan D. Agulnick, Susan Eliazer, Evert Kroon, Emmanuel E. Baetge